Innate Pharma S.A. IPHA
1.51 USD 0.00 (+0.00%)
Nov 10, 2026, 1:55 PM EST
1.47 Day range 1.55
1.17 52-week range 2.71
- YTD
- -13.71%
- 1 year
- -34.35%
News
seekingalpha.com Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript Innate Pharma S.A. (IPHA) Q3 2026 Earnings Call Transcript
marketbeat.com Innate Pharma Q3 Earnings Call Highlights Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the…
benzinga.com Innate Pharma 9M Revenue €3.4M Vs €2.3M YoY, Cash €96.8M; CFO Frédéric Lombard To Step Down December 31 Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person eventLacutamab, partnered with Sobi, progressing toward first…
benzinga.com Innate Pharma H1 2026 Earnings Call Transcript Innate Pharma (NASDAQ:IPHA) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive…
benzinga.com Earnings Scheduled For September 17, 2026 Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on…
benzinga.com Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market session. The company's market cap stands at $243.8 million. As per the news, the Q2 earnings report…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular session. The market value of their outstanding shares is at $9.5 million. Sionna Therapeutics (NASDAQ:SION)…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.6 million. Definium Therapeutics
benzinga.com BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9 BTIG analyst Jeet Mukherjee maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $8 to $9.- benzinga.com HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Innate Pharma (NASDAQ:IPHA) with a Buy and raises the price target from $5 to $7.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
benzinga.com Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy Sobi and Innate Pharma partner for a Phase 3 trial of lacutamab targeting rare skin cancer, featuring a $75 million upfront payment.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report…
benzinga.com Market-Moving News for August 10th BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portuguese National Security Agency ABCL: 24% | AbCellera Reports Phase 2 Trial Results Showing…
benzinga.com Innate Pharma Partners With Sobi To Advance Lacutamab Toward Phase 3, Targets Accelerated Approval Filing In Sézary Syndrome Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndromeMarkus Jensen appointed Chief…- benzinga.com Innate Pharma Completes Phase 1 Enrollment Of Nectin-4 Exatecan ADC IPH4502, Guiding Dose Optimization With Year-End Preliminary Data Readout Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-endFavorable safety profile observed to date, with limited…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Innate Pharma Advances Lacutamab Phase 3 Trial And IPH4502 ADC Amid €25.4M Cash Runway Through Q3 2026 Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation,…- benzinga.com Innate Pharma To Present Phase 2 MATISSE Prospectus Data On IPH5201 Combo In Resectable Lung Cancer At AACR 2026 Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and…
benzinga.com HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $5 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:IPHA) with a Buy and maintains $5 price target.- benzinga.com Earnings Scheduled For March 26, 2026
benzinga.com Innate Pharma FY EPS $(0.64) Beats $(0.65) Estimate, Sales $10.483M Beat $7.230M Estimate Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 1.69 percent increase over losses of $(0.65)…- benzinga.com BTIG Assumes Innate Pharma at Buy, Announces Price Target of $8 BTIG analyst Jeet Mukherjee assumes Innate Pharma (NASDAQ:IPHA) with a Buy rating and announces Price Target of $8.
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Innate Pharma Reports €56.4M Cash And €2.3M Nine-Month Revenue As Lacutamab Advances Toward TELLOMAK-3 Phase 3 Initiation In 2026 Following FDA clearance for confirmatory Phase 3 trial TELLOMAK-3, lacutamab is progressing toward Phase 3 initiation in H1 2026 and potential accelerated approval in Sézary syndromeIPH4502 Nectin-4…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Innate Pharma Gains FDA Clearance To Launch TELLOMAK 3 Phase 3 Trial Of Lacutamab In Sézary Syndrome And Mycosis Fungoides The planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of…
benzinga.com This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - benzinga.com HC Wainwright & Co. Upgrades Innate Pharma to Buy, Announces $5 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Innate Pharma (NASDAQ:IPHA) from Neutral to Buy and announces $5 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday 
benzinga.com Alphabet To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Leerink Partners Downgrades Innate Pharma to Market Perform, Lowers Price Target to $2 Leerink Partners analyst Daina Graybosch downgrades Innate Pharma (NASDAQ:IPHA) from Outperform to Market Perform and lowers the price target from $10 to $2.
- benzinga.com HC Wainwright & Co. Downgrades Innate Pharma to Neutral HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Innate Pharma (NASDAQ:IPHA) from Buy to Neutral.
- benzinga.com Earnings Scheduled For September 17, 2025
- benzinga.com Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0.34) per share from the same period last year. The company reported…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Innate Pharma Presents IPH6501 Preclinical Data At EHA 2025, Highlighting Potential In Relapsed, Refractory, And Untreated CD20+ B-NHL Preclinical data from IPH6501, Innate's proprietary ANKET® targeting CD20, demonstrating potent antitumor activity in vitro on patient-derived samples from Diffuse Large B-Cell Lymphoma (DLBCL) and…
- benzinga.com Earnings Scheduled For March 27, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session